Comparative Pharmacology
Head-to-head clinical analysis: ALBALON versus ALCAFTADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBALON versus ALCAFTADINE.
ALBALON vs ALCAFTADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Category C
Category C
Ophthalmic Antihistamine/Decongestant
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."